[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvalent Cl A (NUVL)

Nuvalent Cl A (NUVL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,757,833
  • Shares Outstanding, K 78,998
  • Annual Sales, $ 0 K
  • Annual Income, $ -425,380 K
  • EBIT $ -439 M
  • EBITDA $ -450 M
  • 60-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.30

Options Overview Details

View History
  • Implied Volatility 8.46% (-0.15%)
  • Historical Volatility 110.49%
  • IV Percentile 5%
  • IV Rank 3.10%
  • IV High 84.44% on 10/31/25
  • IV Low 6.03% on 06/23/26
  • Expected Move (DTE 18) 0.04 (0.03%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 855
  • Volume Avg (30-Day) 2,634
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 37,517
  • Open Int (30-Day) 22,167
  • Expected Range 123.47 to 123.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.44
  • Number of Estimates 6
  • High Estimate $-1.38
  • Low Estimate $-1.48
  • Prior Year $-1.31
  • Growth Rate Est. (year over year) -9.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.30 +41.48%
on 06/08/26
123.69 -0.15%
on 06/26/26
+13.12 (+11.89%)
since 05/29/26
3-Month
87.30 +41.48%
on 06/08/26
123.69 -0.15%
on 06/26/26
+26.85 (+27.78%)
since 03/27/26
52-Week
71.13 +73.64%
on 08/08/25
123.69 -0.15%
on 06/26/26
+43.83 (+55.01%)
since 06/27/25

Most Recent Stories

More News
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

TMHC : 71.78 (-0.04%)
NUVL : 123.51 (-0.01%)
CPRX : 31.46 (-0.13%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, NUVL, AXTA, and PFLC

NEW YORK , June 24, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

TMHC : 71.78 (-0.04%)
PFLC : 17.2100 (-1.40%)
NUVL : 123.51 (-0.01%)
AXTA : 34.01 (-1.42%)
Are ROKU, SLP, NUVL, DAN Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

DAN : 26.48 (-5.87%)
ROKU : 136.53 (+0.83%)
SLP : 18.38 (+0.99%)
NUVL : 123.51 (-0.01%)
Are NUVL, DAN, PAYO Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

DAN : 26.48 (-5.87%)
PAYO : 7.09 (-0.56%)
NUVL : 123.51 (-0.01%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SUNE, NUVL, CCRN, and BGMS

NEW YORK , June 17, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

CCRN : 13.21 (-0.08%)
BGMS : 0.7220 (+20.13%)
NUVL : 123.51 (-0.01%)
SUNE : 2.26 (-8.13%)
MarketBeat Week in Review – 06/08 - 06/12

Stocks rallied on optimism surrounding a potential U.S.-Iran peace deal and SpaceX's historic IPO debut, reinforcing investor confidence and market momentum

NVDA : 194.97 (+1.27%)
GOOGL : 353.65 (+4.82%)
AAPL : 281.74 (-0.72%)
WING : 165.47 (-0.77%)
SPOT : 462.29 (+0.49%)
CBRL : 53.94 (+2.06%)
P : 72.32 (+4.57%)
IREN : 45.91 (-2.75%)
TSLA : 411.84 (+8.46%)
SPCX : 164.19 (+7.15%)
INTC : 131.72 (+2.65%)
NUVL : 123.51 (-0.01%)
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

XOMA : 42.15 (unch)
TBRG : 26.18 (-0.08%)
AVNS : 24.93 (-0.08%)
NUVL : 123.51 (-0.01%)
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

RHHVF : 416.1160 (+0.98%)
NUVL : 123.51 (-0.01%)
GSK : 52.81 (+0.59%)
PFE : 24.37 (+0.33%)
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc ...

NUVL : 123.51 (-0.01%)
GSK : 52.81 (+0.59%)
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE , June 10, 2026 /PRNewswire/ -- Ademi LLP is investigating Nuvalent (NASDAQ: NUVL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

NUVL : 123.51 (-0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 123.68
2nd Resistance Point 123.63
1st Resistance Point 123.57
Last Price 123.51
1st Support Level 123.46
2nd Support Level 123.40
3rd Support Level 123.34

See More

52-Week High 123.69
Last Price 123.51
Fibonacci 61.8% 103.61
Fibonacci 50% 97.41
Fibonacci 38.2% 91.21
52-Week Low 71.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.